Antibe Therapeutics Patents

Patent portfolio assigned to Antibe Therapeutics (verified via public assignee records). Clinical-stage pharma (GI-safe NSAID/pain; lead drug otenaproxesul/ATB-346); acquired by Taro Pharmaceutical Mar 2025. Has patents - e.g. US 8,541,398 assigned to Antibe Therapeutics, plus a later filing extending otenaproxesul IP to 2042; exact total not confirmed. Nuance Biotech is a named China licensing partner (not a paying customer).